Medicenna Therapeutics, Inc.

MDNA · TSX

Public Market Listing

MDNATSX

TSX primary exchange listing

Live quotes, historical charts, and market capitalization for Medicenna Therapeutics, Inc. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
bizaxofuspNo recent activity
Phase 2
IL-4 receptor (IL-4R)Protein / enzyme therapeutic
Glioblastoma
Recurrent Glioblastoma
Phase 1/2
IL-2 receptorProtein / enzyme therapeutic
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
October 2028 (1)
MDNA11Phase 1/2Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer …
Est. primary completion 2028-10-20 · NCT05086692 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.